BRPI0809665B8 - anticorpo monoclonal que se liga especificamente a endosialina - Google Patents

anticorpo monoclonal que se liga especificamente a endosialina

Info

Publication number
BRPI0809665B8
BRPI0809665B8 BRPI0809665A BRPI0809665A BRPI0809665B8 BR PI0809665 B8 BRPI0809665 B8 BR PI0809665B8 BR PI0809665 A BRPI0809665 A BR PI0809665A BR PI0809665 A BRPI0809665 A BR PI0809665A BR PI0809665 B8 BRPI0809665 B8 BR PI0809665B8
Authority
BR
Brazil
Prior art keywords
endosialin
monoclonal antibody
specifically binds
interaction
ligands
Prior art date
Application number
BRPI0809665A
Other languages
English (en)
Portuguese (pt)
Inventor
E Tomkowicz Brian
Grasso Luigi
C Nicolaides Nicholas
M Sass Philip
Zhou Yuhong
Original Assignee
Eisai Inc
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc, Morphotek Inc filed Critical Eisai Inc
Publication of BRPI0809665A2 publication Critical patent/BRPI0809665A2/pt
Publication of BRPI0809665B1 publication Critical patent/BRPI0809665B1/pt
Publication of BRPI0809665B8 publication Critical patent/BRPI0809665B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0809665A 2007-04-05 2008-04-04 anticorpo monoclonal que se liga especificamente a endosialina BRPI0809665B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (3)

Publication Number Publication Date
BRPI0809665A2 BRPI0809665A2 (pt) 2018-12-04
BRPI0809665B1 BRPI0809665B1 (pt) 2021-03-23
BRPI0809665B8 true BRPI0809665B8 (pt) 2021-05-25

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809665A BRPI0809665B8 (pt) 2007-04-05 2008-04-04 anticorpo monoclonal que se liga especificamente a endosialina

Country Status (20)

Country Link
US (4) US7807382B2 (enExample)
EP (2) EP2620451B1 (enExample)
JP (2) JP5825784B2 (enExample)
KR (1) KR101529334B1 (enExample)
CN (1) CN101918446B (enExample)
AU (1) AU2008237296B2 (enExample)
BR (1) BRPI0809665B8 (enExample)
CA (1) CA2682726C (enExample)
CY (2) CY1115370T1 (enExample)
DK (2) DK2137217T3 (enExample)
ES (2) ES2452929T3 (enExample)
HR (2) HRP20140266T1 (enExample)
HU (1) HUE031269T2 (enExample)
LT (1) LT2620451T (enExample)
MX (1) MX2009010701A (enExample)
PL (2) PL2620451T3 (enExample)
PT (2) PT2620451T (enExample)
RS (2) RS55447B1 (enExample)
SI (2) SI2620451T1 (enExample)
WO (1) WO2008124570A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241235B2 (en) 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
ES2452929T3 (es) * 2007-04-05 2014-04-03 Morphotek, Inc. Métodos para inhibir la unión de endosialina a ligandos
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
US9139656B2 (en) 2012-03-30 2015-09-22 Morphotek, Inc. TEM-1 diagnostic antibodies
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
HK1219980A1 (zh) 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE69432926T2 (de) * 1993-02-05 2004-05-13 Epigen, Inc., Wellesley Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
WO1995024483A1 (en) * 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-fb5 antibodies
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
CA2355337A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Method for monitoring arterial oxygen saturation
EP1283905A2 (en) * 2000-03-15 2003-02-19 Epigenomics AG Diagnosis of diseases associated with the cell cycle
AU2001283062A1 (en) 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20070020271A1 (en) * 2003-03-04 2007-01-25 Beverly Teicher Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
ATE493152T1 (de) * 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
EP1819736B1 (en) * 2004-12-03 2010-08-04 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP2292796A1 (en) * 2005-02-10 2011-03-09 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
WO2007111733A2 (en) * 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090239223A1 (en) * 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
US20090176656A1 (en) * 2006-07-21 2009-07-09 Halloran Philip F Tissue rejection
ES2421354T3 (es) 2006-08-11 2013-08-30 Johns Hopkins University Secuencias consenso codificantes de cánceres de mama y colorrectales humanos
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
ES2452929T3 (es) * 2007-04-05 2014-04-03 Morphotek, Inc. Métodos para inhibir la unión de endosialina a ligandos
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
KR20100127768A (ko) * 2008-02-01 2010-12-06 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
EP2677041A3 (en) 2008-02-19 2014-04-09 MDxHealth SA Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010045714A1 (en) 2008-10-20 2010-04-29 University Health Network Methods and compositions for the detection of ovarian cancer
NZ624816A (en) 2009-01-14 2015-07-31 Us Health Ratio based biomarkers and methods of use thereof
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Also Published As

Publication number Publication date
ES2606906T3 (es) 2017-03-28
CN101918446B (zh) 2014-06-18
SI2620451T1 (sl) 2017-01-31
CA2682726C (en) 2017-05-09
PT2620451T (pt) 2016-12-20
WO2008124570A1 (en) 2008-10-16
BRPI0809665A2 (pt) 2018-12-04
PT2137217E (pt) 2014-03-20
CY1118592T1 (el) 2017-07-12
US7807382B2 (en) 2010-10-05
JP2013150618A (ja) 2013-08-08
US8895000B2 (en) 2014-11-25
CN101918446A (zh) 2010-12-15
JP5825784B2 (ja) 2015-12-02
HRP20161715T1 (hr) 2017-02-10
PL2620451T3 (pl) 2017-06-30
US10053509B2 (en) 2018-08-21
BRPI0809665B1 (pt) 2021-03-23
WO2008124570A8 (en) 2008-11-27
US20170029509A1 (en) 2017-02-02
EP2620451A1 (en) 2013-07-31
LT2620451T (lt) 2017-01-10
US20080248034A1 (en) 2008-10-09
DK2620451T3 (da) 2017-01-02
KR20100016221A (ko) 2010-02-12
AU2008237296B2 (en) 2013-07-04
HRP20140266T1 (hr) 2014-04-25
RS53362B (sr) 2014-10-31
EP2137217B1 (en) 2014-03-05
EP2620451B1 (en) 2016-09-14
PL2137217T3 (pl) 2014-08-29
DK2137217T3 (en) 2014-03-17
KR101529334B1 (ko) 2015-06-16
ES2452929T3 (es) 2014-04-03
US20110033455A1 (en) 2011-02-10
MX2009010701A (es) 2010-01-20
CY1115370T1 (el) 2017-01-04
CA2682726A1 (en) 2008-10-16
SI2137217T1 (sl) 2014-07-31
US9505842B2 (en) 2016-11-29
RS55447B1 (sr) 2017-04-28
JP2010523592A (ja) 2010-07-15
US20150079104A1 (en) 2015-03-19
EP2137217A1 (en) 2009-12-30
HUE031269T2 (en) 2017-06-28
AU2008237296A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
EA200970909A1 (ru) Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
MX377283B (es) Célula t o nk que coexpresa un receptor antigénico quimérico (car).
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
CR20120127A (es) Anticuerpos monoclonales
CR20110559A (es) Anticuerpos específicos para cadherina-17
BRPI1013428A2 (pt) anticorpos humanizados para axl
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
BR112015006060A2 (pt) agentes de ligação kir3dl2
CL2012002428A1 (es) Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende.
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
MX373426B (es) Moleculas de enlace a il-18.
ECSP14013307A (es) Genzyme corporation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: EISAI INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF